PuraPharm Corporation Limited (1498.HK)
- Previous Close
0.750 - Open
0.750 - Bid 0.730 x --
- Ask 0.750 x --
- Day's Range
0.750 - 0.750 - 52 Week Range
0.730 - 1.260 - Volume
70,000 - Avg. Volume
47,466 - Market Cap (intraday)
296.923M - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.270 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 31, 2017
- 1y Target Est
--
PuraPharm Corporation Limited, an investment holding company, researches, develops, produces, and sells concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provide Chinese medicine services and concentrated Chinese medicine granules products. In addition, the company engages in the plantation and trading of raw Chinese herbs; and manufacture and sale of traditional Chinese medicine decoction pieces. Further, it provides modernized Chinese medicine services, and Chinese medical diagnostic services. The company sells its products to hospitals, healthcare institutions, and medicine practitioners, as well as operates an online store. The company was founded in 1998 and is headquartered in Tai Po, Hong Kong.
www.purapharm.com662
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 1498.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1498.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1498.HK
Valuation Measures
Market Cap
296.92M
Enterprise Value
701.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.73
Price/Book (mrq)
1.94
Enterprise Value/Revenue
1.72
Enterprise Value/EBITDA
-26.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.07%
Return on Assets (ttm)
-3.66%
Return on Equity (ttm)
-51.56%
Revenue (ttm)
406.86M
Net Income Avi to Common (ttm)
-106.08M
Diluted EPS (ttm)
-0.270
Balance Sheet and Cash Flow
Total Cash (mrq)
20.13M
Total Debt/Equity (mrq)
277.20%
Levered Free Cash Flow (ttm)
75.4M
Company Insights: 1498.HK
1498.HK does not have Company Insights